Nanoviricides (Nanoviricides) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nanoviricides's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nanoviricides could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Nanoviricides's Cash-to-Debt or its related term are showing as below:

NNVC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.67 Med: 57.02 Max: No Debt
Current: 3.5

During the past 13 years, Nanoviricides's highest Cash to Debt Ratio was No Debt. The lowest was 0.67. And the median was 57.02.

NNVC's Cash-to-Debt is ranked worse than
59.78% of 1539 companies
in the Biotechnology industry
Industry Median: 6.46 vs NNVC: 3.50

Nanoviricides Cash-to-Debt Historical Data

The historical data trend for Nanoviricides's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nanoviricides Cash-to-Debt Chart

Nanoviricides Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

11.97

215.97

148.06

No Debt

Nanoviricides Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	4.65	No Debt

Competitive Comparison of Nanoviricides's Cash-to-Debt

For the Biotechnology subindustry, Nanoviricides's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanoviricides's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nanoviricides's Cash-to-Debt falls into.

Nanoviricides Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nanoviricides's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Nanoviricides had no debt ⁽¹⁾.

Nanoviricides's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Nanoviricides had no debt ⁽¹⁾.

Nanoviricides (AMEX:NNVC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nanoviricides Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nanoviricides's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanoviricides (Nanoviricides) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

NV3P:Germany

Address

1 Controls Drive, Shelton, CT, USA, 06484

Website

http://www.nanoviricides.com

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Executives

Makarand Jawadakar	director	C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day	director	C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk	director	C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan	director, 10 percent owner, officer: President	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni	director	C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas	officer: Chief Financial Officer	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour	director, 10 percent owner	666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc.	10 percent owner	135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516